Fri, Jul 25, 2014, 9:21 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Endocyte, Inc. (ECYT) Message Board

  • naked_finger naked_finger Apr 18, 2012 1:02 AM Flag

    Catalysts

    RBC Capital sees several upcoming catalysts for Endocyte, including the resumption of Doxil supply in Q4; and an agreement with the FDA on a Phase III statistical plan in Q3. The firm continues to view the stock as a “compelling investment.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $240M cash and $60M market cap for what Merck just paid $120M upfront to be a part of. Does it need a catalyst?

      • 1 Reply to cash2go
      • EC145: Folate-Receptor Targeted Chemotherapy
        Phase 3 PROCEED trial for patients with platinum-resistant ovarian cancer: currently enrolling.
        Phase 2 PRECEDENT trial for patients with platinum-resistant ovarian cancer: enrollment complete.
        Phase 2 trial for patients with non-small cell lung cancer (NSCLC): currently enrolling.
        Phase 2 trial for patients with non-small cell lung cancer (NSCLC): enrollment complete.
        Phase 2 trial for patients with ovarian cancer: enrollment complete.
        EC17: Folate-Receptor Targeted Hapten
        Phase 1 renal (kidney) cell carcinoma trial: enrollment complete.
        EC0225: Folate-Receptor Targeted Chemotherapy
        Phase 1 solid tumor trial: enrollment complete.
        EC0489: Folate-Receptor Targeted Chemotherapy
        Phase 1 solid tumor trial: enrollment complete.

        http://www.endocyte.com/?page_id=23

        milestone payments

 
ECYT
6.30-0.01(-0.16%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.